NEW YORK (TheStreet) -- Lower gasoline prices help consumers but lower oil prices means lower global demand, which means a slowing economy, Guy Adami, managing director of stockmonster.com, said on CNBC's "Fast Money."
WTI crude oil turned lower in Wednesday's trading session and appears to have taken the broader stock market lower as well, according to Pete Najarian, co-founder of optionmonster.com and trademonster.com.
Lower oil is good for consumers, said Brian Kelly, founder of Brian Kelly Capital, but it hurts many of the U.S. oil producers. Lower pricing may hurt these large employers, which could hurt the economy.
Dan Nathan, co-founder and editor of riskreversal.com, disagreed. He said investors should avoid energy stocks and any large U.S. multinational companies because of the strong U.S. dollar.
Nathan added that Wednesday's price action was bearish, with the S&P 500 hitting resistance near 1,950 and the iShares Russell 2000 ETF (IWM) - Get Report hitting resistance near $110. He is short the SPDR Dow Jones Industrial Average ETF (DIA) - Get Report because many of these companies are not benefiting from lower input costs and will suffer from global exposure.
While the stock market has enjoyed a nice rally over the past few trading sessions, Paul Hickey, co-founder of Bespoke Investment Group, said the ride is unlikely to last. The market will pullback in the next few weeks, which should lead to an attractive buying opportunity headed into the end of the year.
Shares of Boulder Brands (BDBD) slid 24%. It's tempting to buy on this selloff, Najarian said, but it's probably best to wait a few days for a deeper decline. Kelly added that the fundamentals appear to deteriorating. Adami, meanwhile, likes Hain Celestial Group (HAIN) - Get Report on the long side.
iRobot (IRBT) - Get Report climbed 14% and was the first stock on the show's "Pops & Drops" segment. Adam said the stock can move higher, into the $42 to $45 range, which is where investors should consider taking profits.
Broadcom popped 5%. Najarian said the stock is a buy after a pullback.
In order to treat hepatitis C, doctors need to use a strong regiment, said Kleanthis Xanthopoulos, president and CEO of Regulus Therapeutics (RGLS) - Get Report . The stock climbed 103% on Wednesday following positive test results. The company could possibly combine with other hep. C treatment companies, like Merck (MRK) - Get Report , Johnson & Johnson or AbbVie (ABBV) - Get Report .
Merck seems like a buy after the most recent pullback, Najarian said.
For their final trades Nathan is selling Home Depot (HD) - Get Report and Kelly is a seller of the iShares High Yield Corporate Bond ETF (HYG) - Get Report via a long position in put options. Najarian is buying Merck (MRK) - Get Report and Adami said to buy Amgen (AMGN) - Get Report .
-- Written by Bret Kenwell
Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter.